Lumbar Spinal Stenosis is caused by changes in the shape and size of the spinal canal as we age. This natural degenerative process can cause anatomical changes at any time, but is most common in people over 50 years and may continue to progress with age.
Superion® is a completely new, minimally invasive approach to treating lumbar stenosis that fills a gap in the continuum between conservative care and invasive surgery. Designed with patient safety and comfort in mind, Superion® is implanted through a small tube the size of a dime to reduce tissue damage and blood loss. It’s a simple outpatient procedure with a rapid recovery time and no destabilization of the spine.
The Superion® implant acts as an indirect decompression device. Its anatomic design provides optimal fit and preserves a patient’s anatomy and ability to maintain motion. Superion® acts as an extension blocker, relieving pressure on the affected nerves in the manner that one would achieve relief in a seated or flexed position. Available in multiple sizes to accommodate varying patient anatomy, Superion® ensures controlled movement and minimizes post-procedure complications. Superion® was developed to provide patients with a safe and effective alternative when conservative treatment has failed and laminectomy is too aggressive.
FDA approved, Superion® is clinically shown to be effective for up to 60 months. Certain risks are associated with the use of Superion®. Consult your doctor for more information regarding these risks.
Superion® is revolutionizing the treatment of lumbar stenosis. It provides patients with a minimally invasive approach that puts their comfort and safety first, offering the only treatment on the continuum of care between conservative care and surgery.
Providing physicians with more treatment options, and patients with new alternatives for a pain-free life.
Our commitment to excellence and efficacy has led us to conduct the most rigorous FDA clinical trial for lumbar stenosis. Superion® is proven to be durable for up to 48 months, providing patients with a reduction in leg pain by 79% at 48 months.